Literature DB >> 18253950

Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study.

Martina E Spehlmann1, Alexander Z Begun, Jens Burghardt, Patricia Lepage, Andreas Raedler, Stefan Schreiber.   

Abstract

BACKGROUND: Genetic predisposition as a cause of inflammatory bowel disease (IBD) has been proven by both family and twin studies and genetic variants associated with the disease have been identified. The aim of our study was to determine the concordance rates for IBD in German twin pairs and to evaluate clinical characteristics of concordant and discordant twin pairs.
METHODS: Patients with IBD were asked to participate and complete a questionnaire that contained questions about zygosity, demographic data, and medical history.
RESULTS: A total of 189 twin pairs in which at least 1 member had IBD were recruited (68 monozygotic and 121 dizygotic pairs). Within monozygotic pairs, 11 out of 31 (35%) were concordant for Crohn's disease (CD) and 6 out of 37 (16%) for ulcerative colitis (UC). Two of the 58 (3%) dizygotic pairs with CD and 1 out of 63 (2%) dizygotic pairs with UC were concordant for the disease. In 14 out of 20 (70%) discordant monozygotic CD pairs and 25 out of 31 (81%) discordant monozygotic pairs with UC, the first-born was affected by IBD. For discordant dizygotic twins, the first in birth order had IBD in 33 out of 56 (59%) pairs with CD and 40 out of 62 (64.5%) pairs with UC.
CONCLUSIONS: This study confirms a stronger genetic influence in CD than in UC. The high preponderance in being affected of the first-born twin and the fact that concordance was only 35% for CD and 16% for UC monozygotic twins highlight the important role of environmental trigger factors.

Entities:  

Mesh:

Year:  2008        PMID: 18253950     DOI: 10.1002/ibd.20380

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  51 in total

1.  Advances in IBD: Current Developments in the Treatment of Inflammatory Bowel Diseases.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

Review 2.  Crohn's disease: a clinical update.

Authors:  Francis Ha; Hanan Khalil
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 3.  Genetics and pathogenesis of inflammatory bowel disease.

Authors:  Bernard Khor; Agnès Gardet; Ramnik J Xavier
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

Review 4.  Engineering the Microbiome: a Novel Approach to Immunotherapy for Allergic and Immune Diseases.

Authors:  Nan Shen; Jose C Clemente
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

Review 5.  The microbiota in inflammatory bowel disease.

Authors:  Donal Sheehan; Carthage Moran; Fergus Shanahan
Journal:  J Gastroenterol       Date:  2015-03-26       Impact factor: 7.527

Review 6.  Surgical strategies in paediatric inflammatory bowel disease.

Authors:  Colin T Baillie; Jennifer A Smith
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

7.  NOD2 and ATG16L1 polymorphisms affect monocyte responses in Crohn's disease.

Authors:  Dylan M Glubb; Richard B Gearry; Murray L Barclay; Rebecca L Roberts; John Pearson; Jacqui I Keenan; Judy McKenzie; Robert W Bentley
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

Review 8.  Familial aggregation in inflammatory bowel disease: is it genes or environment?

Authors:  Tiago Nunes; Gionata Fiorino; Silvio Danese; Miquel Sans
Journal:  World J Gastroenterol       Date:  2011-06-14       Impact factor: 5.742

Review 9.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  Epigenetics and the developmental origins of inflammatory bowel diseases.

Authors:  Richard Kellermayer
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.